Collaborative Success Stories: Hitting the Marker
University of Missouri researchers have discovered a biomarker that could aid in diagnosis and treatment of prostate cancer.
Prostate cancer is one of the most common types of cancer in men and a leading cause of cancer death. Accurate detection is key to successful treatment; if the cancerous cells spread to other parts of the body, the five-year survival rate drops to below 30 percent. Now, MU researchers have identified a new marker to identify the severity of the disease.
Led by medical researcher Senthil R. Kumar, a team of scientists from MU’s College of Veterinary Medicine and School of Medicine found a genetic biomarker that may offer specific data to diagnosticians. The protein, called TSPYL5, can be used to predict when the cancer may progress aggressively. Additionally, it can be used to identify which treatments may be most effective for individual patients.
“TSPYL5 testing could become one of the tools in our fight against prostate cancer,” says Kumar. “The anticipation is that we can use this biomarker for patients before they undergo any unnecessary and invasive surgeries or drug therapy plans.”
Dr. Senthil R. Kumar is an assistant research professor and serves as assistant director of the College of Veterinary Medicine’s Comparative Oncology Radiobiology and Epigenetics Laboratory.
Click here to download a PDF of this story.
One Health/One Medicine